Newsroom
June 17, 2021
(Editor’s note: This story, originally posted on Feb. 11, 2021, has been updated to include the study’s publication in JAMA Oncology on June 17, 2021.) Contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu SAN ANTONIO (June 17, 2021) — Convalescent plasma therapy was associated with better survival in blood cancer patients hospitalized with COVID-19, especially in sicker patients. […]
June 17, 2021
UT Health San Antonio collaborated with University Health as part of the international COVID-19 Prevention Network and enrolled 176 Novavax clinical trial participants in San Antonio for the Phase 3 study, which is called PREVENT-19.
June 17, 2021
In this video, Dr. Owais Durrani, Emergency Medicine resident physician, discusses the threat of the COVID-19 delta variant in Yahoo! Finance. Watch here.
June 15, 2021
Dr. Jose Cadena Zuluaga, Infectious Diseases, spoke on a Colombia radio program regarding the advantages of Johnson & Johnson’s Janssen vaccine arriving in Colombia. The advantages include that it has only one dose and does not require refrigeration as the other vaccines. Listen here.
June 15, 2021
This Texas Public Radio news brief is about the biotechnology company Novavax releasing Phase 3 clinical trial results. UT Health San Antonio collaborated with University Health as part of the international COVID-19 Prevention Network and enrolled 176 Novavax clinical trial participants in San Antonio for the Phase 3 study, which is called PREVENT-19. Read the story.
June 15, 2021
Dr. Barbara Taylor, Infectious Diseases, and the great work of the Novavax research team of UT Health San Antonio and University Health, are featured in the San Antonio Business Journal. The local site of the international clinical trial by the COVID-19 Prevention Network enrolled more than 175 participants. Read the story.